Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Olmesartan medoxomil
Drug ID BADD_D01603
Description Not Available
Indications and Usage Not Available
Marketing Status Not Available
ATC Code C09CA08
DrugBank ID Not Available
KEGG ID D01204
MeSH ID D000068557
PubChem ID 130881
TTD Drug ID D07UBG
NDC Product Code 62331-056; 64552-4028; 65841-168; 65862-708; 66039-824; 68554-0069; 13668-248; 16729-320; 63629-9426; 68462-438; 71205-174; 72189-137; 62512-0034; 65862-742; 13668-249; 27808-277; 50090-3655; 65162-081; 0527-2426; 70518-2347; 71205-459; 0713-0860; 0713-0861; 65691-0071; 66577-050; 33342-180; 50090-3487; 50228-341; 51407-199; 62332-131; 62332-132; 65862-743; 70518-2127; 70771-1060; 71205-458; 63629-8525; 65862-741; 67877-447; 70771-1059; 15894-0019; 65372-1171; 27808-275; 43547-301; 49252-065; 65162-079; 65597-103; 65597-104; 68382-643; 12666-0021; 64220-123; 66003-104; 16729-322; 43547-300; 46708-132; 46708-133; 62332-133; 63629-8524; 71205-172; 72189-373; 52562-011; 43547-299; 46708-131; 50090-3656; 51407-197; 65162-080; 67877-445; 49587-110; 66003-103; 16729-321; 42571-201; 50228-339; 51407-198; 63629-8523; 67877-446; 68382-645; 0527-2427; 70756-808; 71335-0775; 71335-1920; 0713-0862; 42571-202; 63629-8522; 68462-436; 70756-809; 71335-0817; 71335-0999; 14501-0011; 52038-003; 52038-006; 65015-676; 66577-019; 50228-340; 65597-101; 68382-644; 68462-437; 0527-2425; 70756-810; 70771-1061; 72189-138; 66003-101; 66039-944; 82245-0206; 13668-250; 27808-276; 33342-178; 33342-179; 42571-203; 49252-066; 49252-067
UNII 6M97XTV3HD
Synonyms Olmesartan Medoxomil | Medoxomil, Olmesartan | 5-Methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate - T287346 | Benicar | Olmetec | CS 866 | CS-866 | CS866 | Votum
Chemical Information
Molecular Formula C29H30N6O6
CAS Registry Number 144689-63-4
SMILES CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperkalaemia14.05.03.001--
Hypertriglyceridaemia14.08.02.001--
Hyperuricaemia14.09.01.003--
Influenza like illness08.01.03.010--
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Laboratory test abnormal13.18.01.001--Not Available
Liver function test abnormal13.03.04.030--Not Available
Myalgia15.05.02.001--
Nausea07.01.07.001--
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Pain08.01.08.004--
Pharyngitis11.01.13.003; 07.05.07.004; 22.07.03.004--
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Rhabdomyolysis15.05.05.002--
Rhinitis22.07.03.006; 11.01.13.004--
Sinusitis22.07.03.007; 11.01.13.005--
Tachycardia02.03.02.007--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria10.01.06.001; 23.04.02.001--
Vertigo17.02.12.002; 04.04.01.003--
Vomiting07.01.07.003--
Musculoskeletal discomfort15.03.04.001--Not Available
Transaminases increased13.03.04.036--Not Available
Blood bilirubin abnormal13.03.04.016--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Malnutrition14.03.02.004--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages